Form 4: Agenus Inc. Director Timothy Wright Awarded Stock Options

Director Timothy Wright received 7,500 stock options in Agenus Inc. on February 5, 2024, vesting on February 5, 2025.

Summary

• Timothy Wright, a director of Agenus Inc., was granted 7,500 stock options on February 5, 2024.
• The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.
• The stock options will vest on February 5, 2025.
• The exercise price of the options is $12.60.
• The options expire on February 5, 2034.
• The stock options were granted prior to the 1 for 20 reverse stock split, representing 150,000 Stock Options with an exercise price of $0.63.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that the director is incentivized to contribute to the company's success.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting period of one year encourages continued service and contribution to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their directors and officers.
• The size of the grant is relative to the company's market capitalization and the individual's role and responsibilities.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates